HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Eric Jonasch Selected Research

Renal Cell Carcinoma (Grawitz Tumor)

1/2022Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts?
1/2022A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy.
1/2022From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit.
1/2022Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation.
12/2021Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival.
12/2021Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial.
11/2021Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.
11/2021Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma.
10/2021Author Correction: Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.
9/2021Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Eric Jonasch Research Topics

Disease

133Renal Cell Carcinoma (Grawitz Tumor)
01/2022 - 11/2003
64Neoplasms (Cancer)
04/2022 - 11/2003
19Neoplasm Metastasis (Metastasis)
12/2021 - 03/2005
14Kidney Neoplasms (Kidney Cancer)
01/2022 - 10/2008
11Hypoxia (Hypoxemia)
11/2021 - 05/2009
10Disease Progression
11/2021 - 05/2006
7von Hippel-Lindau Disease (von Hippel Lindau Disease)
04/2022 - 02/2009
7Fatigue
12/2019 - 01/2009
4Carcinoma (Carcinomatosis)
01/2022 - 06/2014
4Carcinogenesis
01/2021 - 06/2014
3Hemangioblastoma
11/2021 - 06/2012
3Pheochromocytoma
10/2018 - 07/2008
3Diarrhea
01/2018 - 01/2009
3Nausea
09/2017 - 09/2011
3Breast Neoplasms (Breast Cancer)
08/2017 - 11/2003
3Hypertension (High Blood Pressure)
10/2015 - 11/2013
2Exanthema (Rash)
04/2021 - 01/2009
2Hand-Foot Syndrome
01/2018 - 10/2014
2Vomiting
09/2017 - 08/2014
2Pneumonia (Pneumonitis)
10/2014 - 03/2014
2Wounds and Injuries (Trauma)
11/2011 - 09/2009
1Microsatellite Instability
04/2022
1Hereditary Neoplastic Syndromes (Cancer Syndrome, Hereditary)
04/2022
1Osteonecrosis (Kienbock's Disease)
01/2022
1Dizziness (Lightheadedness)
11/2021
1Neuroendocrine Tumors (Neuroendocrine Tumor)
05/2021
1Medullary Carcinoma
04/2021
1Urogenital Neoplasms
01/2021
1Anemia
12/2019

Drug/Important Bio-Agent (IBA)

17Tyrosine Kinase InhibitorsIBA
01/2022 - 02/2009
17Biomarkers (Surrogate Marker)IBA
01/2022 - 05/2009
16Sunitinib (Sutent)FDA Link
01/2022 - 07/2008
13Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2022 - 02/2009
13Proteins (Proteins, Gene)FDA Link
01/2021 - 07/2008
11pazopanibFDA Link
01/2019 - 06/2012
10EverolimusFDA Link
09/2021 - 10/2014
10Axitinib (AG 013736)IBA
01/2020 - 11/2011
9Bevacizumab (Avastin)FDA Link
04/2021 - 07/2008
8Immune Checkpoint InhibitorsIBA
04/2022 - 01/2020
8Sorafenib (BAY 43-9006)FDA Link
01/2019 - 07/2008
8TOR Serine-Threonine KinasesIBA
01/2016 - 08/2013
7Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
01/2022 - 10/2015
6GemcitabineFDA Link
08/2017 - 05/2006
6CytokinesIBA
06/2017 - 05/2008
5belzutifanIBA
04/2022 - 01/2021
5DNA (Deoxyribonucleic Acid)IBA
10/2021 - 01/2015
5Capecitabine (Xeloda)FDA Link
08/2017 - 05/2006
4Pharmaceutical PreparationsIBA
04/2022 - 08/2017
4Transcription Factors (Transcription Factor)IBA
11/2021 - 11/2010
4RNA (Ribonucleic Acid)IBA
01/2021 - 05/2013
3NivolumabIBA
01/2022 - 09/2018
3cabozantinibIBA
09/2021 - 09/2020
3Indicators and Reagents (Reagents)IBA
06/2021 - 10/2015
3Oxygen (Dioxygen)IBA
01/2019 - 06/2014
3Protein Isoforms (Isoforms)IBA
07/2018 - 11/2011
3ChromatinIBA
10/2017 - 02/2014
3MTOR InhibitorsIBA
11/2014 - 08/2013
3Biological ProductsIBA
09/2014 - 03/2005
2endothelial PAS domain-containing protein 1IBA
04/2022 - 05/2021
2Retinaldehyde (Retinal)IBA
11/2021 - 10/2018
2EnzymesIBA
01/2019 - 08/2004
2Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA
01/2018 - 01/2015
2Histones (Histone)IBA
08/2016 - 01/2016
2MethyltransferasesIBA
08/2016 - 02/2014
2Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
06/2012 - 02/2009
2Zoledronic Acid (Zometa)FDA Link
12/2011 - 08/2006
2Interferon-alpha (Interferon Alfa)IBA
01/2010 - 11/2006
2Thalidomide (Thalomid)FDA Link
02/2009 - 08/2006
1Poly(ADP-ribose) Polymerase InhibitorsIBA
04/2022
1AntibodiesIBA
01/2022
1sitravatinibIBA
01/2022
1Fentanyl (Sublimaze)FDA LinkGeneric
11/2021
1tremelimumabIBA
11/2021
1Checkpoint Kinase 1IBA
10/2021
1Replication Protein AIBA
10/2021
1Erlotinib Hydrochloride (CP 358,774)FDA Link
04/2021
1Apolipoproteins E (ApoE)IBA
01/2021
1Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
01/2021
1Small Cytoplasmic RNAIBA
01/2021
1lenvatinibIBA
01/2021
1ProteomeIBA
01/2020
1Protein AggregatesIBA
01/2020
1pembrolizumabIBA
01/2020
1pevonedistatIBA
01/2020
1avelumabIBA
01/2020
1IpilimumabIBA
01/2020

Therapy/Procedure

87Therapeutics
04/2022 - 08/2004
28Nephrectomy
12/2021 - 03/2005
7Immunotherapy
12/2021 - 01/2007
4Radiotherapy
01/2022 - 08/2006
3Molecular Targeted Therapy
12/2021 - 07/2008
3Metastasectomy
09/2016 - 08/2009
3Drug Therapy (Chemotherapy)
07/2015 - 01/2007
3Neoadjuvant Therapy
06/2014 - 09/2008
3Cytoreduction Surgical Procedures
07/2012 - 11/2007
2Aftercare (After-Treatment)
05/2013 - 02/2011
2Radiofrequency Ablation
11/2010 - 05/2005
1Contraindications
01/2022
1Nephroureterectomy
01/2022
1Cryosurgery
11/2021